+172.3%
PCAR vs GSK
+48.0%
+124.3%
-27.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.2% | -1.9% | +2.1% | +0.6% |
| 7D | -0.5% | -1.8% | +1.3% | -0.1% |
| 30D | -6.2% | -2.2% | -4.1% | -5.8% |
| 3M | +5.9% | -1.8% | +7.7% | +6.1% |
| 6M | +0.4% | -10.6% | +11.0% | +2.6% |
| YTD | +14.8% | +4.4% | +10.4% | +13.3% |
| 1Y | +30.1% | +30.4% | -0.3% | +21.9% |
| 3Y | +66.7% | +60.1% | +6.6% | +46.5% |
| All | +172.3% | +48.0% | +124.3% | +128.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling